A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects With Selected Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
At a glance
- Drugs XmAb-20717 (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Nevi and melanomas; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Acronyms DUET-2
- Sponsors Xencor
- 05 Nov 2018 According to a Xencor media release, data from this trial is expected in 2019.
- 12 Jul 2018 According to a Xencor media release, first patient has been dosed in this study.
- 24 May 2018 Status changed from not yet recruiting to recruiting.